Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt

References

• Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, Albertson SB, Deshpande A, Farag T, Abebe Z; Global Burden of Disease 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1–22. doi:10.1016/S1473-3099(18)30310-4.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Department of Immunization, Vaccines and Biologicals. Pneumococcal disease. Geneva (CH); 2014 Sep 29 [accessed 2020 Feb 18]. https://www.who.int/immunization/diseases/pneumococcal/en/.
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. The Lancet Global Health. 2018;6(7):e744–57. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Children: reducing mortality. Geneva (CH); 2019 Sep 19 [accessed 2020 Feb 18]. https://www.who.int/news-room/fact-sheets/detail/children-reducing-mortality.
   Google Scholar
• World Health Organization. Global Action Plan. Monitoring evaluation & accountability. Secretariat annual report 2015. Geneva (CH): WHO Press; 2015.
   Google Scholar
• World Health Organization. Weekly epidemiological record. 2012;87:129–144. http://www.who.int/wer
   Google Scholar
• United States Department of Health and Human Services. Centers for disease control and prevention. Pneumococcal vaccination: what everyone should know. Atlanta (GA); 2019 Nov 21 [accessed 2020 Jun 28]. https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html#:~:text=The%20Food%20and%20Drug%20Administration%20(FDA)%20licensed%20the%20first%20pneumococcal,(serotypes)%20of%20pneumococcal%20bacteria .
   Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Hance LF, Reithinger R, Muenz LR, O’Brien KL, Cohen J. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348. doi:10.1371/journal.pmed.1000348.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, McCarthy ND, Petrou S. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51–e59. doi:10.1016/S2214-109X(16)30306-0.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. US. hospitalizations for pneumonia after a decade of pneumococcal vaccination. New Engl J Med. 2013;369(2):155–163. doi:10.1056/NEJMoa1209165.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768. doi:10.1016/S1473-3099(11)70090-1.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648593.
   PubMed Web of Science ®Google Scholar
• Johns Hopkins Bloomberg School of Public Health, International Vaccine Access Center. Global Vaccine Introduction. Baltimore (MD): View-hub; 2019 Mar [assessed 2019 Sep 16]. http://www.jhsph.edu/research/centers-and-institutes/ivac/view-hub.
   Google Scholar
• United States Department of Health and Human Services. Centers for disease control and prevention. Global introduction of new vaccines: delivering more to more. Atlanta (GA); 2018 Mar 20 [accessed 2020 Feb 11]. https://www.cdc.gov/grand-rounds/pp/2018/20180320-new-vaccines.html .
   Google Scholar
• Tricarico S, McNeil HC, Cleary DW, Head MG, Lim V, Yap IKS, Wie CC, Tan CS, Norazmi MN, Aziah I, et al. Pneumococcal conjugate vaccine implementation in middle-income countries. Pneumonia. 2017;9(1):6. doi:10.1186/s41479-017-0030-5.
   Google Scholar
• United States Department of Health and Human Services. Centers for disease control and prevention. Global pneumococcal disease and prevention. Atlanta (GA); 2018 Nov 15 [accessed 2020 Jun 28]. https://www.cdc.gov/pneumococcal/global.html .
   Google Scholar
• Bloom DE, Fan VY, Sevilla JP. The broad socioeconomic benefits of vaccination. Sci Transl Med. 2018;10(441):eaaj2345. doi:10.1126/scitranslmed.aaj2345.
   PubMed Web of Science ®Google Scholar
• Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Munier A, Abo Freikha S, Hoestlandt C, Lara C. Cost-Effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015;33(Suppl 1):A182–A191. doi:10.1016/J.VACCINE.2014.12.044.
   PubMedGoogle Scholar
• Saokaew S, Rayanakorn A, Wu DB, Chaiyakunapruk N. Cost effectiveness of pneumococcal vaccination in children in low- and middle-income countries: a systematic review. PharmacoEconomics. 2016;34(12):1211–1225. doi:10.1007/s40273-016-0439-3.
   PubMed Web of Science ®Google Scholar
• Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, Punpanich W, Teerawattananon Y. Cost-Utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31(26):2839–2847. doi:10.1016/j.vaccine.2013.03.047.
   PubMed Web of Science ®Google Scholar
• Wilson M, Wasserman M, Jadavi T, Postma M, Breton M, Peloquin F, Earnshaw S, McDade C, Sings H, Farkough R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018;7(3):353–371. doi:10.1007/s40121-018-0206-1.
   PubMed Web of Science ®Google Scholar
• Suthipinijtham P, Hemachandra A, Patil S, et al. Modeling the potential impact of pneumococcal conjugate vaccination in Thailand. International Society for Pharamacoeconomic and Outcomes Research Asia Pacific 2018; 2018 September 8–11; Tokyo, Japan.
   Google Scholar
• Wasserman M, Palacios MG, Grajales AG, Baez/revueltas FB, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560–569. doi:10.1080/21645515.2018.1516491.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A, Zollo A, Icardi G. Estimating the clinical and economic impact of switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens. 2020;9(2):[16 p]. doi:10.3390/pathogens9020076.
   PubMed Web of Science ®Google Scholar
• Perdrizet J, Santana CFS, Senna T, et al. Cost-Effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2020 [[accessed 2021 Mar 30]]:[12 p]. doi:10.1080/21645515.2020.1809266.
   PubMed Web of Science ®Google Scholar
• Pugh S, Wasserman M, Moffatt M, Marques S, Reyes JM, Prieto VA, Reijnders D, Rozenbaum MH, Laine J, Åhman H, et al. Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and The Netherlands: a cost-effectiveness analysis. Infect Dis Ther. 2020;9(2):305–324. doi:10.1007/s40121-020-00287-5.
   PubMed Web of Science ®Google Scholar
• Shafie AA, Ahmad N, Naidoo J, Foo CY, Wong C, Pugh S, Tan KK. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Human Vaccines & Immunotherapeutics. 2020;16(7):1719–1727. doi:10.1080/21645515.2019.1701911.
   PubMed Web of Science ®Google Scholar
• Murphy KM, Topel RH. The value of health and longevity. J Polit Econ. 2006;114(5):871–904. doi:10.3386/w11405.
   Web of Science ®Google Scholar
• Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value in Health. 2009;12(4):409–418. doi:10.1111/j.1524-4733.2008.00489.x.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2015. Global Burden of Disease study 2015 (GBD 2015) Socio-Demographic Index (SDI) 1980–2015. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2016.
   Google Scholar
• World Bank, International Comparison Program database. Series name: “GDP per capita, PPP (current international $)”; [accessed 2018 Oct 27]. https://databank.worldbank.org/reports.aspx?source=world-development-indicators .
   Google Scholar
• Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U, Techasaensiri C, Chotpitayasunondh T, Chaiyakunapruk N. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019;37(32):4551–4560. doi:10.1016/j.vaccine.2019.06.015.
   PubMed Web of Science ®Google Scholar
• Aljunid S, Abuduxike G, Ahmed Z, Sulong S, Nur AM, Goh A. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. BMC Infect Dis. 2011;11:248. doi:10.1186/1471-2334-11-248.
   PubMed Web of Science ®Google Scholar
• Chen C, Liceras FC, Flasche S, Sidharta S, Yoong J, Sundaram N, Jit M. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Global Health. 2019;7(1):e58–67. doi:10.1016/S2214-109X(18)30422-4.
   PubMed Web of Science ®Google Scholar
• Chuck AW, Jacobs P, Tyrrell G, Kellner JD. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine. 2010;28(33):5485–5490. doi:10.1016/j.vaccine.2010.05.058.
   PubMed Web of Science ®Google Scholar
• Aljunid S, Maimaiti N, Ahmed Z, Nur AM, Isa ZM, Azmi S, Sulong S. Economic impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian national immunization programme. Value in Health Regional Issues. 2014;3:146–155. doi:10.1016/j.vhri.2014.04.008.
   PubMedGoogle Scholar
• Netsawang S, Punpanich W, Treeratweeraphong V, Chotpitayasunondh T. Invasive pneumococcal infection in urban Thai children: A 10-year review. J Med Assoc Thai. 2010;93(Suppl. 5):S6–12. PubMed: 21298830
   PubMedGoogle Scholar
• Working group of Burden of Disease Project. Nonthaburi: international health policy program. Ministry of public health; Thailand: 2007. Burden of disease and injuries in Thailand; 2004. https://espace.library.uq.edu.au/view/UQ:155542 .
   Google Scholar
• Edmond K, Scott S, Korczak V, Ward C, Sanderson C, Theodoratou E, Clark A, Griffiths U, Rudan I, Campbell H Long term sequelae from childhood pneumonia; systematic review and meta-analysis. PLoS ONE. 2012;7(2):e31239. doi:10.1371/journal.pone.0031239.t001.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease. Institute for Health Metrics and Evaluations (IHME); 2016 [accessed 2018 Oct 24]. http://ghdx.healthdata.org/gbd-results-tool .
   Google Scholar
• Ngo CC, Massa HM, Thornton RB, Cripps AW, Reid S. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS ONE. 2016;11(3):e0150949. doi:10.1371/journal.pone.0150949.
   PubMed Web of Science ®Google Scholar
• Wu DB, Roberts C, Lee VWY, Hong L, Tan KK, Mak V, Lee KKC. Cost-Effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Human Vaccines & Immunotherapeutics. 2016;12(2):403–416. doi:10.1080/21645515.2015.1067351.
   PubMed Web of Science ®Google Scholar
• Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines. 2014;11(10):1235–1247. doi:10.1586/erv.12.99.
   Web of Science ®Google Scholar
• Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018;17(1):71–78. doi:10.1080/14760584.2018.1409116.
   PubMed Web of Science ®Google Scholar
• Castiglia P, Pradelli L, Castagna S, Freguglia V, Palù G, Susanna Esposito S. Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Human Vaccines & Immunotherapeutics. 2017;13(10):2307–2315. doi:10.1080/21645515.2017.1343773.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH, Borrow R. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS ONE. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-Specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. The Lancet. 2014;14(9):839–846. doi:10.1016/S1473-3099(14)70822-9.
   Web of Science ®Google Scholar
• Haasis MA, Ceria JA, Kulpeng W, Teerawattananon Y, Alejandria M, Beall B. Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the philippines. PLoS ONE. 2015;10(7):e0131156. doi:10.1371/journal.pone.0131156.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. The Lancet. 2018;18(4):441–451. doi:10.1016/S1473-3099(18)30052-5.
   Web of Science ®Google Scholar
• National Infectious Disease Register, National Institute for Health and Welfare, THL. Appendix table 1. Data from: “Kopio Liitetaulukot_serotyypit_122019.Xlsx” [dataset]; 2019 [accessed 2021 Jun 23]. https://thl.fi/en/web/thlfi-en/research-and-development/research-and-projects/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland .
   Google Scholar
• Wasfy MO, Pimentel G, Abdel-Maksoud M, Russell KL, Barrozo CP, Klena JD, Earhart K, Hajjeh R. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998–2003. J Antimicrob Chemother. 2005;55(6):958–964. doi:10.1093/jac/dki101.
   PubMed Web of Science ®Google Scholar
• Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12(1):207. http://www.biomedcentral.com/1471-2334/12/207 .
   PubMedGoogle Scholar
• World Health Organization and UNICEF. Estimates of immunization coverage: 2019 revision. Data from: WUENIC_input_to_PDF.Xls. [dataset]. WHO immunization, vaccines and biologicals; 2019 [accessed 2020 Sep 1]. https://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.htm .
   Google Scholar
• Melegaro A, Edmunds WJ. Cost-Effectiveness analysis of pneumococcal conjugate vaccination in England and Walesa. Vaccine. 2004;22(31–32):4203–4214. doi:10.1016/j.vaccine.2004.05.003.
   PubMed Web of Science ®Google Scholar
• van Hoek A, Miller E, Beall B. Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PLoS ONE. 2016;11(2):e0149540. doi:10.1371/journal.pone.0149540.
   PubMed Web of Science ®Google Scholar
• Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E, van Hoek AJ, Arez AP. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS ONE. 2018;13(2):e0192640. doi:10.1371/journal.pone.0192640.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387–394. doi:10.1016/S2213-2600(14)70032-3.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Shen Lim W. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45(6):1632–1641. doi:10.1183/09031936.00183614.
   PubMed Web of Science ®Google Scholar
• O’Brien K, Cohen O, Knoll M, Ramakrishnan M, Farrar J, Pilishvili T, Whitney C, Goldblatt D, Moisi J, de Cola M, et al. Pneumococcal Conjugate Vaccine (PCV) review of impact evidence (PRIME). Summary of findings from systematic review. Johns Hopkins Bloomberg School of Public Health; 2017. https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf .
   Google Scholar
• Patrzałek M, Kotowska M, Goryński P, Albrecht P. Indirect effects of a 7 year PCV7/PCV13 mass vaccination program in children on the incidence of pneumonia among adults: a comparative study based on two polish cities. Curr Med Res Opin. 2016;32(3):397–403. doi:10.1185/03007995.2015.1119676.
   PubMed Web of Science ®Google Scholar
• Bigogo GM, Audi A, Auko J, Aol GO, Ochieng BJ, Odiembo H, Odoyo A, Widdowson MA, Onyango C, Borgdorff MW, et al. Indirect effects of 10-valent pneumococcal conjugate vaccine against adult pneumococcal pneumonia in rural Western Kenya. Clin Infect Dis. 2019;69(12):2177–2184. doi:10.1093/cid/ciz139.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Nunes MC. The potential impact of pneumococcal conjugate vaccine in Africa: considerations and early lessons learned from the South African experience. Human Vaccines & Immunotherapeutics. 2016;12(2):314–325. doi:10.1080/21645515.2015.1084450.
   PubMed Web of Science ®Google Scholar
• Warren JL, Shioda K, Kürüm E, Schuck-Paim C, Lustig R, Taylor RJ, Simonsen L, Weinberger DM. Impact of pneumococcal conjugate vaccines on pneumonia hospitalizations in high- and low-income subpopulations in Brazil. Clinical Infectious Diseases. 2017;65(11):1813–1818. doi:10.1093/cid/cix638.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Afonso ET, Minamisava R, Bierrenbach AL, Cristo EB, Morais Neto OL, Policena GM, Cmas D, Toscano CM. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: a timeseries analysis. PLoS ONE. 2017;12(9):e0184204. doi:10.1371/journal.pone.0184204.
   PubMed Web of Science ®Google Scholar
• Becker GS, Philipson TJ, Soares RR. The quantity and quality of life and the evolution of world inequality. Am Econ Rev. 2005;95(1):277–291. doi:10.3386/w9765.
   PubMed Web of Science ®Google Scholar
• National Transfer Accounts; [accessed 2018 Nov 30]. https://ntaccounts.org/web/nta/show/Browse%20database .
   Google Scholar
• National Transfer Accounts; [accessed 2017 Apr 16]. http://www.ntaccounts.org/doc/repository/NTA%20profiles.xlsx .
   Google Scholar
• International Labour Organization. Data from: ilostat-export.xlsx [dataset]. EGY - EC - Employment, wages and hours of work survey. Mean nominal monthly earnings of employees by sex and economic activity – Harmonized series; 2016 [accessed 2020 May 22]. http://www.ilo.org/ilostat/faces/oracle/webcenter/portalapp/pagehierarchy/Page27.jspx? .
   Google Scholar
• International Labour Organization. Data from: iostat-export.xlsx [dataset]. Mean weekly hours actually worked per employed person by sex and economic activity null; 2016 [accessed 2018 Sep 27].
   Google Scholar
• Turkish Statistical Institute (Turkstat). Data from: average activity time per person by type of activity, sex and age group, 2014-2015 [dataset]. Database: Time Use Survey; 2016 [accessed 2016 Nov 2]. http://www.turkstat.gov.tr/PreTablo.do?alt_id=1009.
   Google Scholar
• Office of National Statistics Algeria. Enquête Nationale Emploi du Temps ENET 2012. Algiers (DZ); 2013 [accessed 2017 Mar 3]. http://www.ons.dz/
   Google Scholar
• Allen RC. Absolute poverty: when necessity displaces desire. Am Econ Rev. 2017;107(12):3690–3721. doi:10.1257/aer.20161080.
   Web of Science ®Google Scholar
• Robinson LA, Hammitt JK, O’Keeffe L. Valuing mortality risk reductions in global benefit-cost analysis. Journal of Benefit Cost Analysis. 2019;10(S1):15–50. doi:10.1017/bca.2018.26.
   PubMedGoogle Scholar
• Pan American Health Organization. Immunization: revolving fund: vaccines. Revolving fund vaccine prices. https://www.paho.org/hq/index.php?option=com_topics&view=rdmore&cid=9979&item=revolving-fund&cat=communication&type=vaccines-9979&Itemid=42192&lang=en.
   Google Scholar
• United Nations, Department of Economic and Social Affairs, Population Division (2015). Data from: WPP2015_SA4_POP_F07_1_POPULATION_BY_AGE_BOTH_SEXES.xlsx [dataset]. World population prospects: the 2015 revision - special aggregates, DVD edition;2015 Dec; [accessed 2016 Oct 26].
   Google Scholar
• United Nations, Department of Economic and Social Affairs, Population Division (2017). Data from: INT/3-1: total population (both sexes combined) by single age, region, subregion and country, annually for 1950-2100 (thousands) [dataset]. World population prospects: the 2017 revision, DVD edition; 2017 Jun [accessed 2019 Feb 22].
   Google Scholar
• World Health Organization. Guide for standardization of economic evaluations of immunization programmes. Geneva (CH); The Department of Immunization, Vaccines and Biologicals; 2008 [accessed 2018 Dec 9]. https://apps.who.int/iris/bitstream/handle/10665/69981/WHO_IVB_08.14_eng.pdf.
   Google Scholar
• International Society for Pharamacoeconomic and Outcomes Research (ISPOR). Pharamacoeconomic guidelines around the world; 2010 Jan 21 [accessed 2020 Jan 23]. https://tools.ispor.org/peguidelines/ .
   Google Scholar
• World Bank national accounts data, and OECD National Accounts data files. Series name: “GDP per capita (current US$)”; [accessed 2018 Oct 18]. https://data.worldbank.org/indicator/PA.NUS.FCRF?end=2016&start=2016 .
   Google Scholar
• Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for development. Cambridge (MA): Center for International Development at Harvard University; 2001. [accessed 2020 Jun 27]. http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf .
   Google Scholar
• Pradhan E, Suzuki EM, Martínez S, Schäferhoff M, Jamison DT. The effects of education quantity and quality on child and adult mortality: their magnitude and their value. In: Bundy D, de Silva N, Horton S, Jaminson D, Patton G, editors. 3rd ed. Washington (DC): International Band for Reconstruction and Development/The World Bank; 2017. p. 423–439. https://www.ncbi.nlm.nih.gov/books/NBK525273/#pt5.ch30.sec4 .
   Google Scholar
• Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the national institute for health and care excellence cost-effectiveness threshold. Health Technol Assess (Rockv). 2015;19(14):1366–5278. doi:10.3310/hta19140.
   Web of Science ®Google Scholar
• Revill P, Ochalek J, Lomas J, Nakamura R, Woods B, Rollinger A, Suhrcke M, Sculper M, Claxton K. Cost-effectiveness thresholds: guiding health care spending for population health improvement. York (UK): Center for Health Economics, University of York; 2015.
   Google Scholar
• World Bank national accounts data, and OECD National Accounts data files. Series name: “Final consumption expenditure (current US$)”; [accessed 2018 Oct 21].
   Google Scholar
• United Nations Population Division. World population prospects: 2017 revision. Series name: “Population, total”; [accessed 2018 Sep 19].https://population.un.org/wpp/Download/Standard/Population/ .
   Google Scholar
• Office of National Statistics Algeria. Consumer spending survey and the standard of living of households 2011 report. Tab. n°20: Salaires nets moyens mensuels par sexe et tranches d’âges. Algiers (DZ); 2014 Nov [accessed 2018 Oct 3]. http://www.ons.dz/IMG/pdf/pubfinsal13-2.pdf .
   Google Scholar
• Statistical Committee of the Republic of Armenia. Data from: LFS_2016.xlsx [dataset]. Labor force survey anonymised micro data database (by household’s members); 2016 [accessed 2018 Oct 3]. https://www.armstat.am/en/?nid=212 .
   Google Scholar
• Republic of Bulgaria, National Statistical Institute. Data from: number of employees, average gross and net hourly earnings and average gross overtime hourly earnings in October 2002 by gender and age - total full-time and part-time employees [dataset]. Time series data on hourly earnings by age; [accessed 2018 Oct 3]. http://www.nsi.bg/en/content/6528/age .
   Google Scholar
• European Commission, Eurostat. Data from: mean hourly earnings by sex, age and occupation – NACE Rev. 2, B-S excluding O (earn_ses14_14) [dataset]. Database: the structure of earnings survey; 2014 [accessed 2016 Aug 18]. http://ec.europa.eu/eurostat/data/database .
   Google Scholar